ESMO 2016 Congress

Oncology Meeting Resources

07 Oct - 11 Oct 2016, Copenhagen, Denmark

ESMO-Congress-2016-square

The annual ESMO congress is the premier scientific platform to present your oncology research and as such, the ultimate learning experience for congress attendees. Find the abstracts, posters, PDF presentation and webcasts from ESMO 2016 to the extent the presenters have consented to release their contribution or a slightly modified version thereof. Please, note that the publication of these presentations is a courtesy of the originating authors and is for personal educational purposes only.

Special Sessions and Tracks

Useful links





Format available

https://oncologypro.esmo.org/Meeting-Resources/ESMO-2016/T-cell-therapy-For-whom-and-when2

Date: 07 Oct 2016
Presenter: Inge-Marie Svane
Resources: Presentation, Webcast
Topic: Immunotherapy

https://oncologypro.esmo.org/Meeting-Resources/ESMO-2016/Back-to-the-basics

Date: 07 Oct 2016
Presenter: Sjoerd van der Burg
Resources: Presentation, Webcast
Topics: Cancer Biology, Immunotherapy, Basic Scientific Principles, Therapy

https://oncologypro.esmo.org/Meeting-Resour...-checkpoints-Do-we-really-know-how-they-work

Date: 07 Oct 2016
Presenter: Ignacio Melero
Resources: Presentation, Webcast
Topics: Immunotherapy, Therapy

https://oncologypro.esmo.org/Meeting-Resources/ESMO-2016/Welcome-to-Copenhagen

Date: 07 Oct 2016
Presenter: Ulrik Lassen
Resources: Webcast

https://oncologypro.esmo.org/Meeting-Resources/ESMO-2016/ESMO-2016-Scientific-address

Date: 07 Oct 2016
Presenter: Andrés Cervantes
Resources: Presentation

https://oncologypro.esmo.org/Meeting-Resour...the-clinical-benefit-of-antineoplastic-drugs

Date: 07 Oct 2016
Presenter: Alberto Sobrero
Resources: Presentation

https://oncologypro.esmo.org/Meeting-Resour...2016/ESMO-Lifetime-Achievement-Award-lecture

Date: 07 Oct 2016
Presenter: Richard Peto
Resources: Presentation

https://oncologypro.esmo.org/Meeting-Resour...-stage-resectable-non-small-cell-lung-cancer

BackgroundNivolumab is a PD-1 inhibitor that has demonstrated durable responses and improved survival in patients (pts) with previously treated, metastatic non-small-cell lung cancer (NSCLC).

Date: 07 Oct 2016
Presenter: Patrick Forde
Resources: Abstract, Presentation, Webcast
Topic: Non-Small Cell Lung Cancer

https://oncologypro.esmo.org/Meeting-Resour...e-IB-to-IIIA-NSCLC-final-results-of-CSLC0501

BackgroundAdjuvant chemotherapy is recommended for completely resected stage II-IIIa NSCLC. Indirect comparison meta-analysis of adjuvant vs neoadjuvant therapy showed no difference in survival.

Date: 07 Oct 2016
Presenter: Yi-Long Wu
Resources: Abstract, Presentation, Webcast
Topic: Non-Small Cell Lung Cancer

https://oncologypro.esmo.org/Meeting-Resour...line-therapy-for-small-cell-lung-cancer-SCLC

BackgroundAlisertib, a selective AAK inhibitor, showed single-agent antitumor activity in preclinical in vivo SCLC models and was synergistic with P in this setting. We report the efficacy (PFS, OS, ORR) and safety from this study.

Date: 07 Oct 2016
Presenter: Taofeek Owonikoko
Resources: Abstract, Presentation, Webcast
Topic: Small Cell Lung Cancer